BioPharma Dive October 22, 2024
Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.
Thorsten Stafforst remembers being told to stop wasting his time.
It was early last decade and scientists across the world were buzzing over a new tool, called CRISPR, that could precisely alter human DNA. Working in the German college town of Tubingen, Stafforst and fellow researchers at the local university were instead engrossed by the prospect of rewriting RNA, DNA’s chemical cousin.
“Everybody told me, ‘Why do you want to edit RNA?’” Stafforst said. “You can edit DNA now; that doesn’t make sense.”
Yet in 2012 they and, shortly afterwards, a group at the...
Today's Sponsors
Today's Sponsor